GLP-1 Daily: Ozempic & Wegovy News
Lilly Says Retatrutide Beat Ozempic Head-to-Head; HHS Lets Pharmacies Compound Six Unapproved Peptides; What's Really Mixed Into Compounded GLP-1s
Thursday, October 29, 2026 · 7 min
Eli Lilly reports company topline phase 3 results showing its experimental retatrutide beat Ozempic 2 mg on blood sugar and weight in type 2 diabetes, with more side-effect dropouts. HHS paused enforcement against pharmacies compounding six unapproved peptides, and a JAMA study from Nebraska finds compounded GLP-1s widely mixed with B12 and other additives.
Listen
Show notes
Eli Lilly reports company topline phase 3 results showing its experimental retatrutide beat Ozempic 2 mg on blood sugar and weight in type 2 diabetes, with more side-effect dropouts. HHS paused enforcement against pharmacies compounding six unapproved peptides, and a JAMA study from Nebraska finds compounded GLP-1s widely mixed with B12 and other additives.
In this episode
- Lilly's 'triple-G' drug tops Novo's Ozempic in diabetes trial — Jonathan Gardner
“Those benefits appear to come with a trade-off. In the study, only 3% of Ozempic recipients stopped treatment because of side effects compared with 8% of the people on the highest retatrutide dose and 5% of those in the 9 mg group.”
- RFK Jr. takes shortcut to make some unapproved peptides available for use — NBC News
“In a notice filed Wednesday, the agency said it would exercise “enforcement discretion,” meaning it will not take legal action against compounding pharmacies that make the six unapproved peptides. In practice, that means these pharmacies can start offering them now, even though…”
- Compounded GLP-1s Coformulated With B12, Other Additives — Marilynn Larkin
“Compounded GLP-1s contain ingredient combinations not found in FDA-approved products, introducing uncertainty about composition, purity, and potency, according to a new study. The authors argue this warrants mandatory testing and adverse-event reporting for mass-compounded…”